Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

Alterations of p53 are common in early stage prostate cancer.

Downing SR, Russell PJ, Jackson P.

Can J Urol. 2003 Aug;10(4):1924-33. Review.

PMID:
14503938
2.
3.

p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein.

Griewe GL, Dean RC, Zhang W, Young D, Sesterhenn IA, Shanmugam N, McLeod DG, Moul JW, Srivastava S.

Prostate Cancer Prostatic Dis. 2003;6(4):281-5.

PMID:
14663467
4.

p53 protein and gene alterations in pathological stage C prostate carcinoma.

Salem CE, Tomasic NA, Elmajian DA, Esrig D, Nichols PW, Taylor CR, Skinner DG, Roy-Burman P, Lieskovsky G, Cote RJ.

J Urol. 1997 Aug;158(2):510-4.

PMID:
9224335
5.

Detection of human papillomavirus DNA and p53 gene mutations in human prostate cancer.

Suzuki H, Komiya A, Aida S, Ito H, Yatani R, Shimazaki J.

Prostate. 1996 May;28(5):318-24.

PMID:
8610059
6.

The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.

Smith ND, Rubenstein JN, Eggener SE, Kozlowski JM.

J Urol. 2003 Apr;169(4):1219-28. Review.

PMID:
12629332
8.

Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis.

Kim MJ, Bhatia-Gaur R, Banach-Petrosky WA, Desai N, Wang Y, Hayward SW, Cunha GR, Cardiff RD, Shen MM, Abate-Shen C.

Cancer Res. 2002 Jun 1;62(11):2999-3004.

9.

Mutation of the tumor suppressor gene p53 in human prostate and bladder cancers--investigation by temperature gradient gel electrophoresis (TGGE).

Schlechte HH, Schnorr D, Löning T, Rudolph BD, Pohrt UM, Loening SA.

J Urol. 1997 Mar;157(3):1049-53.

PMID:
9072541
10.

p53 gene alterations in human prostate carcinoma.

Effert PJ, McCoy RH, Walther PJ, Liu ET.

J Urol. 1993 Jul;150(1):257-61.

PMID:
8510267
11.

Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer.

Zhou Z, Flesken-Nikitin A, Corney DC, Wang W, Goodrich DW, Roy-Burman P, Nikitin AY.

Cancer Res. 2006 Aug 15;66(16):7889-98.

12.

Immunohistochemical determination of p53 protein in prostatic cancer and prostatic intraepithelial neoplasms.

Yaman O, Ozdiler E, Orhan D, Sak SD, Baltaci S, Tulunay O, Göğüş O.

Urol Int. 1997;58(4):199-202.

PMID:
9253117
13.

An uncertain role for p53 gene alterations in human prostate cancers.

Brooks JD, Bova GS, Ewing CM, Piantadosi S, Carter BS, Robinson JC, Epstein JI, Isaacs WB.

Cancer Res. 1996 Aug 15;56(16):3814-22.

14.

Profiling of gene expression changes caused by p53 gain-of-function mutant alleles in prostate cancer cells.

Tepper CG, Gregg JP, Shi XB, Vinall RL, Baron CA, Ryan PE, Desprez PY, Kung HJ, deVere White RW.

Prostate. 2005 Dec 1;65(4):375-89.

PMID:
16037992
15.

p53 immunohistochemical and genetic alterations are associated at high incidence with post-irradiated locally persistent prostate carcinoma.

Prendergast NJ, Atkins MR, Schatte EC, Paulson DF, Walther PJ.

J Urol. 1996 May;155(5):1685-92.

PMID:
8627854
16.
17.
18.

p53 is mutated in a subset of advanced-stage prostate cancers.

Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred DC.

Cancer Res. 1993 Jul 15;53(14):3369-73.

19.

Mutation and expression analysis of the p73 gene in prostate cancer.

Yokomizo A, Mai M, Bostwick DG, Tindall DJ, Qian J, Cheng L, Jenkins RB, Smith DI, Liu W.

Prostate. 1999 May;39(2):94-100.

PMID:
10221564
20.

HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer.

Montironi R, Mazzucchelli R, Barbisan F, Stramazzotti D, Santinelli A, Scarpelli M, Lòpez Beltran A.

Hum Pathol. 2006 Sep;37(9):1137-44. Epub 2006 Jun 21.

PMID:
16938518

Supplemental Content

Support Center